Q2040 HCPCS code: Tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion

Q2040 is the HCPCS Level II code for tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion. CMS terminated Q2040 on 2018-12-31; do not bill it for later dates of service. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case.

Code details

FieldValue
SectionQ codes — Temporary codes
Coverage codeC — Carrier judgment
Pricing indicator51 — Drug or biological (priced per ASP/average sales price rules)
BETOS categoryO1E — Other drugs
Added2018-01-01
Last action effective2019-01-01
Terminated2018-12-31

What changed for Q2040

Frequently asked questions

What is HCPCS code Q2040?

Q2040 is the HCPCS Level II code for tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion. Short descriptor: "Tisagenlecleucel car-pos t".

Does Medicare cover Q2040?

Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.

Related Q20 codes

Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.

Next steps

Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.

All Q codes · HCPCS lookup